

**CLAIMS**

1. Use of escitalopram comprising less than 3% w/w of R-citalopram for the preparation of a pharmaceutical composition.  
5
2. The use according to claim 1, characterised in that escitalopram is used as an oxalate salt, preferably a crystalline oxalate salt.
3. The use according to claim 1 or 2, characterised in that escitalopram comprising not  
10 more than 2% w/w R-citalopram is used.
4. The use according to claim 3, characterised in that escitalopram comprising not more  
than 1% w/w.
- 15 5. The use according to any of Claims 1 – 4, characterised in that the pharmaceutical composition is for treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-menstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder or drug abuse.  
20
6. The use according to Claim 5, characterised in that the pharmaceutical composition is for treatment of major depression disorder.
7. The use according to Claim 5, characterised in that the medicament is for treatment  
25 of a neurotic disorder.
8. The use according to any of Claims 5 to 7, characterised in that the pharmaceutical composition is for treatment of patients who have failed to respond to initial treatment with a conventional SSRI.  
30
9. The use according to Claims 8, characterised in that the pharmaceutical composition is for treatment of patients with major depression disorder who have failed to

respond to initial treatment with a conventional SSRI.

10. Pharmaceutical composition, characterised in that it comprises escitalopram with less than 3% w/w of R-citalopram as an active ingredient.
- 5
11. Pharmaceutical composition of claim 10, characterised in that it comprises escitalopram with not more than 2% w/w of R-citalopram as an active ingredient.
- 10
12. Pharmaceutical composition according to claim 11, characterised in that it comprises escitalopram with not more than 1% w/w.
13. Pharmaceutical composition according to any of claims 10 to 12, characterised in that it is a unit dose preparation containing 2.5 to 20 mg escitalopram.
- 15
14. Pharmaceutical composition according to claim 13, characterised in that it is a unit dose preparation containing not more than 10 mg escitalopram.
- 15
15. Pharmaceutical composition according to claim 14, characterised in that it is a unit dose preparation containing not more than 7.5 mg escitalopram, preferably 5.0 mg.
- 20
16. Pharmaceutical composition according to any of claims 10 to 15, characterised in that it is a oral formulation, preferably a tablet.
17. Use of escitalopram for the treatment of major depression disorder characterised in that it is used in a daily dose of less than 10 mg of escitalopram.
- 25
18. Use of escitalopram for the treatment of major depression disorder characterised in that it is used in a daily dose of 7.5 mg or less of escitalopram.
19. Use of escitalopram for the treatment of major depression disorder characterised in that it is used in a daily dose of 5.0 mg of escitalopram.
- 30